Skip to content
10-Q

Quarterly Report

INTEGRATED BIOPHARMA INC INBP

0001437749-25-034076

← back to feed
Filed
Nov 10, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Nov 10, 2025 31.06M sh
Shares Diluted Q1 2026 · Sep 30, 2025 31.42M sh
Shares Diluted Q1 2026 · Sep 30, 2024 30.65M sh
Capex Q1 2026 · Sep 30, 2025 $173K
Capex Q1 2026 · Sep 30, 2024 $56K
Operating Cash Flow Q1 2026 · Sep 30, 2025 $1.3M
Operating Cash Flow Q1 2026 · Sep 30, 2024 $657K
Cash And Equivalents Q1 2026 · Sep 30, 2025 $4.73M
Cash And Equivalents Q1 2026 · Jun 30, 2025 $3.62M
Stockholders Equity Q1 2026 · Sep 30, 2025 $20.49M
Stockholders Equity Q1 2026 · Jun 30, 2025 $20.32M
Stockholders Equity Q1 2026 · Sep 30, 2024 $19.55M
Stockholders Equity Q1 2026 · Jun 30, 2024 $19.24M
Current Liabilities Q1 2026 · Sep 30, 2025 $4.76M
Current Liabilities Q1 2026 · Jun 30, 2025 $4.25M
Total Liabilities Q1 2026 · Sep 30, 2025 $5.05M
Total Liabilities Q1 2026 · Jun 30, 2025 $4.58M
Current Assets Q1 2026 · Sep 30, 2025 $19.62M
Current Assets Q1 2026 · Jun 30, 2025 $18.76M
Total Assets Q1 2026 · Sep 30, 2025 $25.54M
Total Assets Q1 2026 · Jun 30, 2025 $24.9M
Eps Diluted Q1 2026 · Sep 30, 2025 $0.00
Eps Diluted Q1 2026 · Sep 30, 2024 $0.01
Eps Basic Q1 2026 · Sep 30, 2025 $0.00
Eps Basic Q1 2026 · Sep 30, 2024 $0.01
Sga Expense Q1 2026 · Sep 30, 2025 $856K
Sga Expense Q1 2026 · Sep 30, 2024 $881K
Net Income Q1 2026 · Sep 30, 2025 $123K
Net Income Q1 2026 · Sep 30, 2024 $259K
Operating Income Q1 2026 · Sep 30, 2025 $163K
Operating Income Q1 2026 · Sep 30, 2024 $490K
Gross Profit Q1 2026 · Sep 30, 2025 $1.02M
Gross Profit Q1 2026 · Sep 30, 2024 $1.37M
Cost Of Revenue Q1 2026 · Sep 30, 2025 $11.67M
Cost Of Revenue Q1 2026 · Sep 30, 2024 $12.25M